

## Vasicine and structurally related quinazolines

Kunal Nepali · Sahil Sharma · Ritu Ojha ·  
Kanaya Lal Dhar

Received: 31 December 2011 / Accepted: 20 February 2012 / Published online: 10 March 2012  
© Springer Science+Business Media, LLC 2012

**Abstract** Natural products are diverse sources of important chemical constituents. Most of the metabolites isolated from them are heterocycles possessing diverse pharmacological actions. Vasicine, a heterocyclic alkaloid possessing a privileged quinazoline nucleus is primarily present in the leaves of the plant *Adhatoda vasica nees*, family Acanthaceae. Vasicine and structurally related quinazolines have been an area of interest for the researchers all around the world. The present review provides an up to date compilation of the alkaloid vasicine, its biosynthesis, synthesis, biological attributes, design of its synthetic analogues along with structurally related quinazolines.

**Keywords** Quinazoline · Antitussive · Synthesis ·  
Bronchodilator · Alkaloid

### Introduction

Natural products are diverse sources of important chemical constituents. Most of the metabolites isolated from them are heterocycles possessing diverse pharmacological actions. Vasicine, a heterocyclic alkaloid possessing a privileged quinazoline nucleus is primarily present in the leaves of the


plant *Adhatoda vasica nees*, family Acanthaceae (Atal, 1980). *Adhatoda vasica* is a small, evergreen shrub with a multitude of uses in traditional Ayurveda (Chopra, 1982). The plant is distributed throughout India up to an altitude of 1,300 m and mainly found in sub-Himalayan regions; also found in Nepal, Pakistan, Myanmar and Germany (Ali, 1998). Leaves are simple, petiolate, ex-stipulate, 10–20 cm long and 3–10 cm broad, lanceolate having crenate margin, tapering base and an acuminate apex with characteristic odour and bitter taste (Satakopan and Thomas, 1970). The plant, particularly the leaves are used for the treatment of respiratory ailments (Hooper, 1888). Chopra (1982) explored the potential of the plant as antitubercular agent. *Adhatoda vasica* is also believed to have abortifacient properties. It is used in some parts of India to stimulate uterine contractions, thus speeding childbirth (Satakopan and Thomas, 1970). Vasicine was first isolated as a pure alkaloid by Hooper (1888) from the leaves of *Adhatoda vasica*. The chemical investigation of this alkaloid was carried out in detail after it was again isolated by Sen and Ghose (1924). After a lot of contradictions (Ghose *et al.*, 1932; Spath and Nikawitz, 1934; Reynolds and Robinson, 1934; Mooris *et al.*, 1935; Spath and Platzer, 1935; Spath *et al.*, 1935) the structure of vasicine was finally established to be a tricyclic heterocycle (Fig. 1). The pharmacological profile of the plant is mainly attributed to the presence of number of alkaloids among which vasicine is the major one (Shrivastava *et al.*, 2006; Maikhuri and Gangwar, 1965; Dhar *et al.*, 1981). In addition to vasicine, the leaves and roots of *Adhatoda* contain the alkaloids L-vasicinone, deoxyvasicine, maiontone, vasicinolone and vasicinol (Jain and Sharma, 1982).

Detailed pharmacological investigation on bronchodilatory potential of vasicine was carried out by Chopra and Ghosh (1925). It was reported to cause relaxation of

---

K. Nepali (✉) · S. Sharma · R. Ojha  
Department of Pharmaceutical Sciences,  
Guru Nanak Dev University,  
Amritsar 143005, Punjab  
e-mail: Kunal\_8855@rediffmail.com

K. L. Dhar  
Laboratory for Drug Design and Synthesis,  
Department of Pharmaceutical Chemistry,  
Indo-Soviet Friendship (ISF) College of Pharmacy,  
Moga 142001, Punjab, India

**Fig. 1** Structure of vasicine

tracheal muscle at low concentrations and contraction at high concentrations. It also exhibited protection against histamine-induced bronchospasm (Cambridge *et al.*, 1962; Lahiri and Pradhan, 1964).

Another alkaloid vasicinone, an auto-oxidation product of vasicine, was also reported to cause bronchodilatory effect both in vitro and in vivo (Amin *et al.*, 1963). Bhide *et al.* (1974, 1976) reported that vasicinone (Fig. 2) was more potent than vasicine and possessed antiasthmatic activity comparable to that of sodium cromoglycate.

Atal (1980), after an in depth study on pharmacological, toxicological and pharmacokinetic studies, reported that vasicine is highly active as bronchodilatory agent both in vitro and in vivo, and its activity is comparable to theophylline. Vasicine was also highlighted as potential oxytocic, abortifacient agent and uterotonic (Wakhloo *et al.*, 1979; Gupta *et al.*, 1977; Tothill, 1967; Chan *et al.*, 1963; Chandhok *et al.*, 1978).

### Biosynthesis of vasicine




Number of theories and supporting evidences has been proposed for the biosynthesis of the quinazoline alkaloids. However, the below-mentioned pathway seems to be the most probable (Groger and Mornas, 1960; Johne and Groger, 1968; Johne *et al.*, 1968; Liljegren, 1968; Leete, 1967; Liljegren, 1971) (Fig. 3).

### Synthesis

Schopf and Oechler (1936) scheme involved the synthesis of vasicine from 2-aminobenzaldehyde and  $\gamma$ -amino- $\alpha$ -hydroxybutyraldehyde (Leonard and Martell, 1960) (Fig. 4).

DL-Vasicine was prepared by Southwick and Casanova (1958) in a six-step sequence starting from *O*-nitrobenzylamine (Mohrle and Gundlach, 1970) (Fig. 5).


Another reaction scheme for improving the yield was proposed (Wasserman and Kuo, 1991) where 2-aminobenzylamine employed acted as a trinucleophile, forming the tricyclic carbon skeleton of vasicine (threefold donor-acceptor process) (Fig. 6).

**Fig. 2** Structure of vasicinone**Fig. 3** Biosynthesis of quinazoline alkaloids**Fig. 4** Schopf and Oechler scheme


### Synthesis of vasicinone

Eguchi *et al.* (1996) reported the synthesis of racemic vasicinone from 3-hydroxy- $\gamma$ -lactam and anthranilic acid (Fig. 7) and the synthesis of (*S*)-vasicinone from *L*-aspartic acid and anthranilic acid utilizing intramolecular aza-Wittig reaction (Fig. 8).


A convenient route to both (*S*)- and (*R*)-vasicinone was also reported for the asymmetric oxidation of deoxyvasicinone by employing (*R*)- and (*S*)-Davis reagents. The results showed that *L*-vasicinone has the (*S*)-configuration (Fig. 9).



**Fig. 5** Synthesis of DL-vasicine




**Fig. 6** Synthesis of vasicine



\*TBDMS= tert-butyldimethylsilyl


**Fig. 7** Synthesis of DL-vasicinone via intramolecular aza-Wittig reactions



\*TBDMS= tert-butyldimethylsilyl


**Fig. 8** Synthesis of L-vasicinone via intramolecular aza-Wittig reaction

**Fig. 9** Synthesis of vasicinone by Davis reagent




Chemical as well as enzymatic methods for the synthesis of bronchodilatory pyrrolo [2,1-*b*]quinazoline alkaloids (azidoreductive cyclization strategy) utilizing TMSCl-NaI


and bakers' yeast in good yields was reported by Kamal *et al.* (2001) (Fig. 10). Vasicinone was synthesized as well as resolved by using different lipases (Fig. 11).



**Fig. 10** Synthesis of vasicinone



**Fig. 11** Chemical and enzymatic method for the synthesis of vasicinone



R = Electron withdrawing group

**Fig. 12** Synthesis of deoxyvasicinone

#### Synthesis of deoxyvasicinone

Deetz *et al.* (2001) presented a one-step method for the preparation of highly functionalized 4(3*H*)-quinazolinone derivatives (Fig. 12).

An efficient procedure for preparation of 4(3*H*)-quinazolinone (deoxyvasicinone) has been established by the reaction of lactam-HCl salts with  $\text{POCl}_3$  followed by cyclization with methyl anthranilate by Lee *et al.* (2003) (Fig. 13).

Liu *et al.* (2005) reported the syntheses of deoxyvasicinone and 8-hydroxyvasicinone via novel microwave-assisted domino reactions (Fig. 14).

Bowman *et al.* (2007) proposed a method for the synthesis of deoxyvasicinone which involved cyclisation of alkyl radicals (Fig. 15).

Kamal *et al.* (2004) have demonstrated an efficient, cost-effective and ecofriendly protocol for the synthesis fused [2,1-*b*]quinazolinone systems (Fig. 16).


#### Stereochemistry and nomenclature of vasicine

After lot of contradictions, the configuration at C-3 has been found to 3*S* (Joshi *et al.*, 1994; 1996) (Fig. 17).

Earlier vasicine was numbered according to fused pyrrolo quinazoline system (Manske and Holmes, 1972–1976; 1953) (Fig. 18). This numbering system was later changed (Fig. 19). At present, the IUPAC name which is being used is shown below (Fig. 20).

#### Semisynthetic derivatives of vasicine

Bromhexine, a semisynthetic derivative of the alkaloid vasicine and its metabolite are widely used mucolytic



Deoxyvasicinone (n=1, R=H)

8-Hydroxydeoxyvasicinone (n=1, R=OH)

**Fig. 14** Synthesis of deoxyvasicinone

agents (Grange and Snell, 1996). Ambroxol is the principal metabolite of Bromhexine (Fig. 21).

Vasicine when investigated was not found to inhibit the growth of *Mycobacterium tuberculosis* (Chopra and Ghosh, 1925). However, distillate from the plant exhibit in vitro antimycobacterial effects (Gupta and Chopra, 1954) which indicated that vasicine might not be the active constituent.

Inhibitory effects of benzylamines on mycobacteria were reported by Meindl *et al.* (1984). Piacenza (1966) reported the antitubercular effect of Bromhexine given to patients as an expectorant.


Bromhexine exhibited pH-dependent growth inhibition of strains of *M. tuberculosis* in a study conducted by Medical Research Council of Ireland.

Grange and Snell (1996) reported the inhibitory effects of Ambroxol, which is a principal metabolite of the Bromhexine for the first time.






#### Extraction of vasicine

An improved process for the isolation of vasicine from the *Adhatoda vasica*, comprises of the below-mentioned steps (Chattopadhyay *et al.*, 2003):

- Preparation of alcoholic extract of dried and pulverized leaves at an ambient temperature.
- Concentrating the alcoholic extract to obtain a concentrated extract.
- Treating and stirring the extract with an aqueous organic acid (preferably citric acid) for 2–24 h.
- Extracting the acid solution with an organic solvent (preferably dichloromethane).



**Fig. 13** Synthesis of deoxyvasicinone

**Fig. 15** Synthesis of deoxyvasicinone**Fig. 16** Synthesis of deoxyvasicinone**Fig. 17** Structure of vasicine with S configuration at C-3**Fig. 18** Structure of vasicine**Fig. 19** Structure of vasicine**Fig. 20** 1,2,3,9-tetrahydropyrrolo [2,1-b]quinazolin-3-ol

- e. Separating the organic layer and aqueous acidic layer.
- f. Basifying the aqueous acidic solution with a base (preferably aqueous ammonia).
- g. Extracting the basified solution with an organic solvent (preferably chloroform).
- h. Separating the organic layer, drying and filtering.
- i. Evaporating the organic layer to obtain an amorphous residue.
- j. Treating the amorphous residue with an organic solvent or mixture of organic solvents to obtain vasicine

(preferred solvent used is a mixture of petroleum ether–acetone in the ratio 1:1 to 2:1).


The vasicine obtained by this method has a minimum purity of 80%. The earlier reported procedures had following disadvantages: The procedure reported by Atal (1980) involved following steps:

- a. Extracting the leaves of the plant with 95% alcohol. Preparation of alcoholic extract of leaves of the plant.
- b. Treating the concentrated alcoholic extract with aqueous 2% H<sub>2</sub>SO<sub>4</sub>.
- c. Basifying the aqueous acidic solution with ammonia and extracting with chloroform.
- d. Concentrating the chloroform layer and the residue again dissolved in aqueous 2% H<sub>2</sub>SO<sub>4</sub>.
- e. Repeating the process of basification with ammonia, followed by extraction with chloroform.


The drawback of this procedure is that it involves use of strong mineral acid like H<sub>2</sub>SO<sub>4</sub> for extraction which result in considerable degradation of vasicine, which is further aggravated by repeating the process of same mineral acid treatment twice.

Mehta *et al.* (1963) also reported a procedure which involved following steps:

- a. The leaves were refluxed with 90% alcohol.
- b. The solvent was evaporated and the alcoholic extract obtained was dissolved with hot distilled water.
- c. The aqueous extract was filtered.
- d. Filtrate was extracted with chloroform to remove the colouring matters and then made alkaline with 5% caustic soda, and again extracted with chloroform.
- e. The combined chloroform extracts were extracted with 5% hydrochloric acid, and then acidic solution was made alkaline with ammonia and again extracted with chloroform.




**Fig. 21** Vasicine and its semisynthetic derivatives



**Fig. 22** SAR of vasicine

**Fig. 23** Ring A of deoxyvasicinone substituted with alkoxy group




- f. After repeating the process twice the final chloroform extract was concentrated to give a crude total alkaloid from which vasicine was isolated as vasicine hydrochloride with 2 g yield.

The first drawback of the above process includes the extraction of the alcohol extract with hot water, which further has two drawbacks:

- Vasicine could not be quantitatively extracted from its aqueous solution.
- Hot water extraction will convert vasicine into its auto-oxidation product vasicinone.

#### Medicinal attributes

Vasicine has been reported to produce bronchodilation (Chopra and Ghosh, 1925), bronchoconstriction (Amin



**Fig. 24** Synthesis of deoxyvasicinone



*et al.*, 1963), relaxation of tracheal muscle at low concentration, contraction at high concentration and protection against histamine-induced bronchospasm (Cambridge *et al.*, 1962), slight relaxation of tracheal chain and protection against histamine-induced bronchospasm in guinea pigs (Lahiri and Pradhan, 1964). Vasicine possesses uteronic stimulating and oxytocic activity and causes abortifacient effects by the release of prostaglandins under the influence of oestrogens (Gupta *et al.*, 1978).

#### Bronchodilatory action of vasicine


Vasicine was found to have bronchodilatory activity both in vitro and in vivo, its activity was comparable to



**Fig. 25** Structures of deoxyvasicinone, vasicinone, vasicine




**Fig. 26** The N–N–O triangle




**Fig. 27** Bond distance (Å) in N–N–O triangles

**Fig. 28** Deoxyvasicinone with  $n = 1-4$



**Fig. 29** Structure of dihomologue analogue



theophylline while vasicinone showed bronchodilatory activity in vitro and in vivo. The two alkaloids in combination showed more bronchodilatory activity both in vivo and in vitro. Relaxant effect of vasicine, vasicinone and theophylline was seen only when the tracheal chain was in contracted state. Vasicine showed inhibition of histamine-induced bronchoconstriction in anaesthetized guinea pigs (Collier *et al.*, 1960).

#### Antioxidant and anti-inflammatory activity of vasicine

In a study to investigate antioxidant and anti-inflammatory activity of alkaloid (Srinivasarao *et al.*, 2006), significant decrease in lipid peroxidation and significant increase in antioxidants superoxide dismutase, catalase, glutathione peroxidase and reduced glutathione was observed with vasicine.

#### Abortifacient and oxytocic activity

Vasicine possesses uterotonic activity, oxytocic and abortifacient activity (Gupta *et al.*, 1977). The uterotonic activity of vasicine was investigated on the uteri of different species of animals and in different hormonal states and was found to be similar to oxytocin and methyl ergometrine. The uterotonic effect was influenced by the degree of priming of the uterus by oestrogens which are known to enhance the synthesis of prostaglandins in the uterus (Atal, 1980).

Vasicine in oestradiol primed guinea pigs showed abortifacient effect. The effect was enhanced in oestradiol pretreatment and reduced after pretreatment with indomethacin and aspirin. Thus it was clear that the abortifacient effect of vasicine was mediated through the release of prostaglandins.


#### Seasonal variation of vasicine

Pandita *et al.* (1983) reported that the plant *Adhatoda vasica* was rich in its alkaloidal content in the months of August–October. The total alkaloid content was about 2% out of which vasicine was about 95%.


Seasonal variation of vasicine in *Adhatoda vasica* and *A. beddomie* has been reported by Bagchi *et al.* (2003). And the study revealed that vasicine content in both the species peaked during of March and September coinciding with flowering time with higher concentration in March.

#### SAR studies on vasicine


The detailed SAR has been represented diagrammatically (Fig. 22).



**Fig. 30** Synthesis of the seven-membered analogue



**Fig. 31** Synthesis of benzylamine derivatives of the seven membered analogue



\*The numbering given by the authors does not correspond to the one reported earlier.

**Fig. 32** Synthesis of 8,9-dimethoxy derivative

#### Ring A modification

SAR studies on vasicine revealed no enhancement of activity on different substitutions on Ring A (Atal *et al.*, 1979) (Fig. 23).

#### Ring B modification

Deoxyvasicinone having a carbonyl function at C-9 was synthesized (Fig. 24). The molecule showed significant bronchodilatory potential.


Detailed investigation on the deoxyvasicinone and comparison with vasicinone (oxidative product of vasicine having two oxygen functions at C-3 and C-9) lead to the conclusion that only one oxygen function is required for

bronchodilatory activity as vasicinone was found to be devoid of any bronchodilatory effects (Fig. 25). This was proved by scientists of IIM (CSIR), Jammu. Though there are contradictory reports about the potential of vasicinone as Bronchodilator.

Thus only one oxygen function and the N–N–O triangle (Fig. 26) was proposed to be the necessary condition which is present in both deoxyvasicinone and vasicine. Both deoxyvasicinone and vasicine are having identical triangles with same bond length are formed (Fig. 27).


#### Ring C modification

Ring C plays a significant role in the enhancement of the bronchodilator potential of the molecule (Fig. 28).




**Fig. 33** Synthesis of 2,3-diethoxy derivative


**Fig. 34** Synthesis of 2,3-diethoxy-6,7,8,9,10,12-hexahydroazepino [2,1-*b*]quinazolin-12-one



**Fig. 35** Dibromo derivative of deoxyvasicinone



**Fig. 36** Mackinazolinone



Molecules with  $n = 1-4$  were synthesized. A remarkable increase in the bronchodilatory potential activity was observed when the size of the ring was increased till  $n = 3$ , i.e. the dihydro analogue. In fact the dihydro analogue was found to be the most potent bronchodilator of the series. The molecule with  $n = 4$  showed decrease in activity which led to the conclusion that  $n$  should not be greater than 3. The seven-membered analogue was found to be 6–10 times more potent than aminophylline on dose basis.

#### Dihydro analogue of deoxyvasicinone

The seven-membered ring derivative (Fig. 29) was synthesized by Sharma *et al.* (1993) of IIM, Jammu (Fig. 30).



#### Pharmacological evaluation deoxydihomo “C” vasicinone

Pharmacological investigations showed that the deoxydihomo “C” vasicinone possessed potent bronchodilatory activity which was proved by number of in vivo and in vitro experiments. Isolated guinea pig tracheal chain was employed for the invitro experiments. Its bronchodilatory activity was recorded against both spasmogens and antigen-induced bronchoconstriction in the sensitized tissues. Mediation of the effect by direct action on the smooth muscles like aminophylline and not through the adrenoreceptor stimulation was the mechanism which was revealed after lot of study. Toxicological studies were also satisfactory (Nepali *et al.*, 2010).

Further research carried on this dihydro analogue


Jindal *et al.* (2002) synthesized various derivatives of deoxydihomo vasicinone with decreased activity than the lead (Fig. 31) and also reported 8,9-dimethoxy derivative to have significant bronchodilatory potential (Fig. 32). A group of scientists from R.R.L., Jammu led by Zabir (2005) again synthesized (Fig. 33) and evaluated some novel quinazolinone derivative for bronchodilatory activity and reported that 2,4-diethoxy-6,7,8,9,10,12-hexahydroazepino[2,1-*b*]quinazolin-12-one possesses marked bronchodilator activity evaluated on contracted trachea or constricted tracheo-bronchial tree. On intestinal smooth muscle too it showed relaxant effect. Tracheal relaxant effect was not found to be mediated through  $\beta$ -adrenoceptors. Cumulative dose–response study with acetylcholine and histamine indicated for its non-specific direct effect on smooth muscles. It was found to be more potent than theophylline

**Fig. 37** Synthesis of mackinazolinone



**Fig. 38** Synthesis of mackinazolinone

**Fig. 39** Synthesis of mackinazolinone



and less to that of salbutamol on dose basis. It was found devoid of anti-allergic activity. It was also found to be free from any adverse effect. Mahindroo *et al.* (2005) reported a derivative of deoxydihomo analogue having significant bronchodilatory potential (Fig. 34) Nepali *et al.* (2010) while exploring the antitussive effect of dihydro deoxyvasicinone synthesized various derivatives and reported 2,4-dibromo-7,8,9,10-tetrahydroazepino[2,1-*b*]quinazolin-12(6H) one to be a potent antitussive (Fig. 35). The compound caused notable decrease in cough frequency and increase in cough latency in citric acid-induced cough model in guinea pigs. Compound showed notable antitussive effect as compared with codeine (10 mg/kg).


### Structurally related alkaloid: mackinazolinone and isaindigotone

#### Mackinazolinone

Mackinazolinone (Fig. 36), an quinazolinone alkaloid fused with a piperidine ring system, was isolated (Johns and Lamberton, 1965; Fitzgerald *et al.*, 1966) from *Mackinalaya* species.

#### Synthesis

Spath and Ruffner (1938) synthesized mackinazolinone by the reduction of pyridoquinazoline (Fig. 37).



**Fig. 40** Isaindigotone


Kametani *et al.* (1977) synthesized mackinazolinone in good yields from the reaction of the unstable sulfonamide anhydride with 2-pyrrolidone (Fig. 38).

Liu *et al.* (2005) carried out the synthesis of mackinazolinone via novel microwave-assisted domino reaction (Fig. 39).

Mackinazolinone possesses a broad spectrum of pharmacological activities (Johns and Lamberton, 1965; Fitzgerald *et al.*, 1966).



**Isaindigotone** An alkaloid having deoxyvasicinone as a core structural unit (Fig. 40). Isaindigotone was isolated from the root of *Isatis indigotica* Fort, which is a biennial herbaceous plant widely present in China (Wu *et al.*, 1997). Its chemical structure comprises of the deoxyvasicinone moiety conjugated with a substituted benzylidene.

Pan *et al.* (2008) prepared deoxyvasicinone by the condensation of 2-pyrrolidone and methyl anthranilate in the presence of phosphorous oxychloride and then the



**Fig. 41** Synthesis of isaindigotone

**Fig. 42** Synthesis of isaindigotone



**Fig. 43** Isaindigotone

treatment of deoxyvasicinone with 3,5-dimethoxy-4-hydroxybenzaldehyde gave isaindigotone by the Claisen–Schmidt condensation (Molina *et al.*, 2001) (Fig. 41).

Liu *et al.* (2005) reported a novel three-component one-pot total synthesis of isaindigotone promoted by microwave irradiation (Fig. 42).

Isaindigotone was assigned as E configuration on the basis of the Nuclear Overhauser Enhancement Spectroscopy (NOESY). On irradiation of the proton H-7, only enhancement of the equivalent protons H-6 and H-2 was observed. Moreover, on irradiation of the equivalent protons H-6 and H-2, signal of protons H-7 and H-2 was enhanced, respectively (Liu *et al.*, 2005) (Fig. 43). Isaindigotone (Wu *et al.*, 1997; Molina *et al.*, 2001; Liu *et al.*, 2005) exhibit anti-inflammatory, antimicrobial and antidepressant activities.

Alkaloid isaindigotone is reported to have antinociceptive, anti-inflammatory, and antipyretic effects in animal study (Ho and Chang, 2002). Alkaloid isaindigotone and its

derivatives are also reported to have inhibitive function on leukocytes and act as a scavenger of superoxide either through the hypoxanthine/xanthine oxidase system or through stimulated human neutrophils (Molina *et al.*, 2001).

## Conclusion

The overall conclusion of the review is that vasicine is a privileged phytoconstituent with number of medicinal attributes. Moreover, the up to date compilation of the literature on the molecule will make it convenient for the researchers to further explore the potential of the molecule by synthesizing various analogues taking vasicine as a lead.

## References

- Ali M (1998) Textbook of pharmacognosy, 1st edn. CBS Publishers and Distributors, New Delhi
- Amin AH, Mehta DR, Samarth SS (1963) Proceedings First Intern. Pharmacological Meeting Stockholm. Pergamon Press Ltd, Oxford
- Atal CK (1980) Chemistry and pharmacology of vasicine—a new oxytocic and abortifacient. Raj Bandhu Industrial Co, New Delhi, p 148
- Atal CK, Sharma RL, Dhar KL (1979) Chemistry and pharmacology of vasicine—a new oxytocic & abortifacient synthesis of deoxydihomo “C” vasicinone. Indian J Chem 18b:444–450
- Bagchi GD, Dwivedi PD, Haider F, Singh S, Srivastava S, Chattopadhyay SK (2003) Seasonal variation in VASICINE

- contents in *Adhatoda* species grown under north Indian plain conditions. *J Med Arom Plants* 25:37–40
- Bhide MB, Naik PV, Ghooi RB (1974) Studies on the pharmacological evaluation of vasicine and vasicinone. In: Xth Scientific Seminar in Indian Medicine Institute of Medical Sciences, Banaras Hindu University, Banaras, India
- Bhide MB, Naik PV, Haramsheth DR (1976) Recent advances in pharmacology of antiasthmatic drugs of Indian origin. In: U.G.C. Seminar on Recent advances in chemistry and pharmacology of Indian plant drugs, Vishakapatnam, India
- Bowman WR, Elsegood MRJ, Stein T, Weaver GW (2007) Radical reactions with 3H-quinazolin-4-ones: synthesis of deoxyvasicinone, mackinazolinone, luotonin A, rutaecarpine and tryptanthrin. *Org Biomol Chem* 5:103–113
- Cambridge GW, Jansen ABA, Jarman DA (1962) Bronchodilating action of vasicinone and related compounds. *Nature* 196:1217
- Chan WY, Connel MO, Pomery SR (1963) Effects of the estrous cycle on the sensitivity of rat uterus to oxytocin and desamino-oxytocin. *Endocrinology* 72:279
- Chandhok N, Gupta OP, Atal CK (1978) Abortifacient activity of the alkaloid vasicine through the release of prostaglandins. *J Steroid Biochem* 9:885
- Chattopadhyay SK, Bagchi GD, Dwivedi PD, Srivastava S (2003) Process for the production of vasicine. United States Patent 6676976
- Chopra RN (1982) Indigenous drugs of India. Academic Publishers, Calcutta
- Chopra R, Ghosh S (1925) Some observations on the pharmacological actions and therapeutic properties of *Adhatoda vasica*. *Indian J Med Res* 13:205–212
- Collier HOJ, Holgate JA, Schachter M, Shorley PG (1960) The bronchoconstrictor action of bradykinin in the guinea-pig. *Br J Pharmacol* 15:290
- Deetz MJ, Malerich JP, Beatty AM, Smith BD (2001) One-step synthesis of 4(3H) quinazolinones. *Tetrahedron Lett* 42:1851–1854
- Dhar KL, Jain MP, Koul SK, Atal CK (1981) Vasicol, a new alkaloid from *Adhatoda vasica*. *Phytochemistry* 20:319
- Eguchi S, Suzuki T, Okawa T, Matsushita Y (1996) Synthesis of optically active vasicinone based on intramolecular aza-Wittig reaction and asymmetric oxidation. *J Org Chem* 61:7316–7319
- Fitzgerald JS, Johns SR, Lambertson JA, Redcliffe AH (1966) 6,7,8,9-Tetrahydropyridoquinazolines, a new class of alkaloids from *Mackinlaya* species (Araliaceae). *Aust J Chem* 19:151
- Ghose TP, Krishna S, Narang KS, Ray JN (1932) Vasicine. *J Chem Soc* 2740:105
- Grange JM, Snell NJ (1996) Activity of bromhexine and ambroxol, semi-synthetic derivatives of vasicine from the Indian shrub *Adhatoda vasica* against *Mycobacterium tuberculosis* in vitro. *J Ethnopharmacol* 50:49–53
- Groger D, Mornas K (1960) On the biogenesis of peganine. *Arch Pharm* 293:1049–1052
- Gupta KC, Chopra IC (1954) Antitubercular effect of an extract of *Adhatoda vasica*. *Nature* 173:1194
- Gupta OP, Sharma ML, Ghatak Ray BJ, Atal CK (1977) Potent uterine activity of alkaloid vasicine. *J Med Res* 66:680
- Gupta OP, Anand KK, Ghatak BJR, Atal CK (1978) A promising uterotonic abortifacient. *Indian J Exp Biol* 16:1075–1077
- Ho YL, Chang YS (2002) Studies on the antinociceptive, anti-inflammatory and anti pyretic effects of *Isatis indigotica* root. *Phytomedicine* 9:419–424
- Hooper ID (1888) Isolin from *Adhatoda vasica* Nees, Acanthaceae. *J Pharm* 18:841–842
- Jain MP, Sharma VK (1982) Phytochemical investigation of roots of *Adhatoda vasica*. *Planta Med* 46:250
- Jindal DP, Bhatti RS, Ahlawat S, Gupta S (2002) Synthesis and bronchodilatory activity of some nitrogen bridgehead compounds. *Eur J Med Chem* 37:419–425
- Johne S, Groger D (1968) Investigation in the biosynthesis of peganines (vasicine) *Engl Sum. Phytochemistry* 7:429
- Johne S, Groger D, Richter G (1968) Contribution to the biosynthesis of peganine in *Adhatoda vasica*-D alkaloid inst auto radiography succinic-acid malic-acid aspartic-acid anthranilic-acid glutamine amino-acids. *Arch Pharm* 301:721
- Johns SR, Lambertson JA (1965) Alkaloids of *Mackinlaya* species (Family Araliaceae). *Chem Commun* 267:83
- Joshi BS, Bai Y, Puar MS, Dubose KK, Pelletier SW (1994) <sup>1</sup>H and <sup>13</sup>C-NMR assignments for some pyrrole [2, b]-quinazoline alkaloids of *A. vasica*. *J Nat Prod* 57:953–996
- Joshi BS, Newton MG, Lee DW, Barber AD, Pelletier SW (1996) Reversal of absolute stereochemistry of the pyrrolo [2,1-b]quinazoline alkaloids vasicine, vasicinone, vasicinol and vasicinone. *Tetrahedron Asymmetry* 7:25–28
- Kamal A, Ramana KV, Rao MV (2001) Chemoenzymatic synthesis of pyrrolo[2,1-b]quinazolinones: lipase-catalyzed resolution of vasicinone. *J Org Chem* 66:997–1001
- Kamal A, Ramana AV, Reddy KS, Ramana KV, Babu AH, Prasad BR (2004) One pot conversion of azido arenes to N-arylacetyl amides and N-arylformamides: synthesis of 1,4-benzodiazepine-2,5-diones and fused [2,1-b]quinazolinones. *Tetrahedron Lett* 45:8187–8190
- Kametani T, Loc CV, Higa T, Koizumi M, Ihara M, Fukumoto K (1977) Iminoketene cycloaddition. 2. Total syntheses of arboline, glycosminine, and rutaecarpine by condensation of iminoketene with amides. *J Am Chem Soc* 99:2306
- Lahiri PK, Pradhan SN (1964) Pharmacological investigation of vasicinol an alkaloid from *Adhatoda vasica* Nees. *Indian J Exp Biol* 2:219
- Lee ES, Park J, Jahng Y (2003) A facile synthesis of simple alkaloids-synthesis of 2,3-polymethylene-4(3H)-quinazolinones and related alkaloids. *Tetrahedron Lett* 44:1883–1886
- Leete E (1967) Biogenesis of natural compounds. Pergamon press, Oxford
- Leonard NJ, Martell MJ (1960) Laboratory realization of the Schöpf-Oechler scheme of vasicine synthesis. *Tetrahedron Lett* 1:44
- Liljgren DR (1968) The biosynthesis of quinazoline alkaloids of *Peganum harmala* L. *Phytochemistry* 7:1299
- Liljgren DR (1971) Biosynthesis of quinazoline alkaloids of *Peganum harmala*. *Phytochemistry* 10:2661–2669
- Liu J, Ye P, Sprague K, Sargent K, Yohannes D, Baldino CM, Wilson CJ, Shi-Chung NG (2005) Novel one-pot total syntheses of deoxyvasicinone, mackinazolinone, isaindigotone, and their derivatives promoted by microwave irradiation. *Org Lett* 7:3363–3366
- Mahindroo N, Zabeer A, Bhagat A, Bedi KL, Khajuria KR, Kapoor VK, Dhar KL (2005) Synthesis and structure-activity relationships of vasicine analogues as bronchodilatory agents. *Med Chem Res* 14:347–368
- Maikhuri RK, Gangwar AK (1965) Ethnobiological notes on the Khasi and Garo tribes of Meghalaya Northeast India. *Econ Bot* 47:345
- Manske RHF, Holmes HL (1953) The alkaloids. Incorporated Publishers, New York
- Manske RHF, Holmes HL (1972–1976) The alkaloids. Incorporated Publishers, New York
- Mehta DR, Naravane JS, Desai RM (1963) Vasicinone. A bronchodilator principle from *Adhatoda vasica* Nees (N. O. Acanthaceae). *J Org Chem* 28:445
- Meindl WR, von Angerer E, Schonenberger H, Ruckdeschel G (1984) Benzylamines: synthesis and evaluation of antimycobacterial properties. *J Med Chem* 27:1111–1118

- Mohrle H, Gundlach P (1970) Eine neue synthese für DL-vasicin. *Tetrahedron Lett* 11:3249
- Molina P, Ta'rraga A, Gonzalez-Tejero A, Rioja I, Ubeda A, Terencio MC, Alcaraz MJ (2001) Inhibition of leukocyte functions by the alkaloid isaindigotone from *Isatis indigotica* and some new synthetic derivatives. *J Nat Prod* 64:297–1300
- Mooris RC, Hanford WE, Adams R (1935) Structure of vasicine. III. Position of the hydroxyl group. *J Am Chem Soc* 57:951–954
- Nepali K, Bande MS, Sapra S, Garg A, Kumar S, Sharma P, Goyal R, Satti NK, Suri OP, Dhar KL (2010) Antitussive effects of azepino[2,1-b]quinazolones. *Med Chem Res*. doi:10.1007/s00044-011-9641-1
- Pan L, Tan J, Hou J, Huang S, Gu L, Huang Z (2008) Design, synthesis and evaluation of isaindigotone derivatives as acetylcholinesterase and butyrylcholinesterase inhibitors. *Bioorg Med Chem Lett* 18:3790–3793
- Pandita K, Bhatia MS, Thappa RK, Agarwal SG, Dhar KL, Atal CK (1983) Seasonal variation of alkaloids of *Adhatoda vasica* and detection of glycosides and N-oxides of vasicine and vasicinone. *Planta Med* 48:81–82
- Piacenza F (1966) Desirable side effects of an expectorant. *Deutsche Med J* 17:226–228
- Reynolds TM, Robinson R (1934) Constitution of vasicine. *Nature* 134:142
- Satakopan S, Thomas PJ (1970) Note on adulterant of vasaka. *Indian J Pharm* 32:66–67
- Schopf C, Oechler F (1936) Zur Frage der Biogenese des Vasicins (Peganins). Die Synthese des Desoxyvasicins unter physiologischen Bedingungen. *Justus Liebigs Ann Chem* 523:1–29
- Sen JN, Ghose TP (1924) Alkaloid from leaves of *Adhatoda vasica*. *J Indian Chem Soc* 1:315
- Sharma SD, Gupta VK, Goswami KN, Padmanabhan VM (1993) Crystal structure of deoxy vasicine zinc complex. *Cryst Res Technol* 28:1115
- Shrivastava N, Shrivastava A, Banerjee A, Nivsakar M (2006) Anti-ulcer activity of *Adhatoda vasica* Nees. *J Herb Pharmacother* 6:43–49
- Southwick PL, Casanova L (1958) A new synthesis of DL-vasicine and a methoxy analog. *J Am Chem Soc* 80:1168–1173
- Spath E, Nikawitz E (1934) Die Konstitution des Peganins. *Eur J Inorg Chem* 67:45
- Spath E, Platzer N (1935) Über Derivate des Peganins und ihre Ring-Homologen (VIII. Mitteil. Über Peganin). *Eur J Inorg Chem* 68:2221
- Spath E, Ruffner F (1938) Über das Pyracridon (=  $\alpha$ -Chinochinolon) (XIV. Mitteil. über Peganin). *Eur J Inorg Chem* 71:1657
- Spath E, Kuffner F, Platzer N (1935) Synthese und Konstitution des Peganins (Vasicins). *Eur J Inorg Chem* 68:699–702
- Srinivasarao D, Jayaraj IA, Jayaraj R, Prabha ML (2006) A study on antioxidant and anti-inflammatory activity of vasicine against lung damage in rats. *Indian J Allergy Asthma* 20:1–7
- Tothill A (1967) Investigation of adrenaline reversal in the rat uterus by the induction of resistance to isoprenaline. *Br J Pharmacol* 29:291
- Wakhloo RL, Wakhloo D, Gupta OP, Atal CK (1979) Vasicine hydrochloride: a new drug for interruption of pregnancy. *J Obstet Gynaecol India* 29:939
- Wasserman HH, Kuo GH (1991) The chemistry of vicinal tricarbonyls. An efficient synthesis of ( $\pm$ )-vasicine. *Tetrahedron Lett* 32:7131–7132
- Wu X, Qin G, Cheung KK, Cheng KF (1997) New alkaloids from *Isatis indigotica*. *Tetrahedron* 53:13323–13328
- Zabir A, Bhagat A, Gupta OP, Singh GD, Youssouf MS, Dhar KL, Suri OP, Suri KA, Satti NK, Gupta BD, Qazi GN (2006) Synthesis and bronchodilator activity of new quinazolin derivative. *Eur J Med Chem* 41:429–434